{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nbevacizumab: Given IV\n\nlenalidomide: Given orally\n\ndexamethasone: Given orally","id":"OG000","title":"Bevacizumab, Dexamethasone, and Lenalidomide"}],"populationDescription":"Outcome measure data were not collected.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Local Cytokine Milieu Using Tissue Micro Arrays of Bone Marrow Biopsy Specimens","type":"SECONDARY"}